BiotechTube

Placebo + MAT9001 (omega-3 pentaenoic acid)

Phase 3Withdrawn
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Severe Hypertriglyceridemia

Conditions

Severe Hypertriglyceridemia

Trial Timeline

Jun 1, 2021 → Oct 1, 2022

NCT ID
NCT04662528

About Placebo + MAT9001 (omega-3 pentaenoic acid)

Placebo + MAT9001 (omega-3 pentaenoic acid) is a phase 3 stage product being developed by Matinas Biopharma for Severe Hypertriglyceridemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04662528. Target conditions include Severe Hypertriglyceridemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04662528Phase 3Withdrawn

Competing Products

20 competing products in Severe Hypertriglyceridemia

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
80
Drotrecogin alfa (activated)Eli LillyPhase 2
52
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
CS-3150Daiichi SankyoPhase 3
77
tacrolimusAstellas PharmaApproved
85
enzalutamideAstellas PharmaPhase 1
33
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
77
AlefaceptAstellas PharmaApproved
85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
65
CefiderocolShionogiApproved
85
eritoran tetrasodium + PlaceboEisaiPhase 3
77
Donepezil HClEisaiApproved
85
Donepezil Hydrochloride (Aricept)EisaiApproved
85
KHK4827 + PlaceboKyowa KirinPhase 3
77

Other Products from Matinas Biopharma

MAT2203 + Amphotericin BPhase 3
69
Oral Encochleated Amphotericin B (CAMB)Phase 2
44
Amphotericin BPhase 2
44
Omega 3 pentaenoic acid + icosapent ethylPhase 2
44
Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB)Phase 2
44